Pentoxifylline-ZZ prolonged-acting pills 400mg, 20pcs

Composition

One tablet contains: Active ingredient: pentoxifylline in terms of 100% substance – 400 mg. Auxiliary substances: calcium stearate, potato starch, hypromellose (hydroxypropylmethylcellulose), lactose monohydrate (milk sugar), povidone (polyvinylpyrrolidone low molecular weight). Shell composition: hypromellose (hydroxypropylmethylcellulose), polysorbate 80 (tween-80), Acryl-iz (copolymer of methacrylic acid with ethyl acrylate 1: 1 (40.0%), titanium dioxide (15.0%), talc (37.25%), triethyl citrate (4.8%), colloidal anhydrous silicon oxide (1.25%), sodium bicarbonate (1.2%), sodium lauryl sulfate (0.5%)), acidic red 2C or dye azorubin (carmoisine).

Pharmacological action

Means that improves microcirculation, angioprotector. A derivative of dimethylxanthine. Pentoxifylline reduces blood viscosity and increases the elasticity of red blood cells, improves microcirculation and increases the concentration of oxygen in the tissues. The increased elasticity of red blood cells is probably due to inhibition of phosphodiesterase and an increase in cAMP content in red blood cells as a result. A decrease in blood viscosity may be due to a decrease in the concentration of fibrinogen in plasma and suppression of aggregation of red blood cells and platelets.

Indications

Peripheral circulatory disorders (including intermittent claudication) associated with chronic occlusive circulatory disorders in the arterial vessels of the lower extremities. Ischemic cerebral stroke; disorders of blood supply to the brain due to atherosclerosis; dyscirculatory encephalopathy. Trophic disorders of tissues and organs associated with arterial or venous thrombosis, varicose veins, frostbite. Diabetic angiopathy. Acute ischemic neuropathy of the optic nerve, acute obstruction of the central retinal artery.

Use during pregnancy and lactation

No adequate and well-controlled clinical studies have been conducted on the safety of pentoxifylline in pregnancy. Pentoxifylline and its metabolites are excreted in breast milk. If necessary, use during lactation should stop breastfeeding.

Contraindications

Acute myocardial infarction, massive bleeding, retinal hemorrhage, brain hemorrhage, simple diabetic and proliferating diabetic retinopathy.

Side effects

From the digestive system: possible nausea, vomiting, pain and heaviness in the epigastrium, diarrhea. From the cardiovascular system: possible tachycardia, palpitation, pain behind the sternum, a feeling of warmth to the face. With intravenous or intra-arterial use, blood pressure may decrease. From the central nervous system: possible headache, dizziness. Allergic reactions: skin rash, pruritus, urticaria. From the side of the blood coagulation system: rarely and mainly in the presence of risk factors-bleeding.

Interaction

Pentoxifylline may potentiate the effect of antihypertensive drugs. Against the background of parenteral use of pentoxifylline in high doses, it is possible to increase the hypoglycemic effect of insulin in patients with diabetes mellitus. When used concomitantly with ketorolac, it is possible to increase the risk of bleeding and/or increase prothrombin time; with meloxicam, it is possible to increase the risk of bleeding;with sympatholytics, ganglioblockers and vasodilators, it is possible to lower blood pressure;with heparin, fibrinolytic drugs, it is possible to increase the anticoagulant effect. Cimetidine significantly increases the concentration of pentoxifylline in the blood plasma, and therefore, with simultaneous use, the likelihood of side effects may increase.

How to take, course of use and dosage

Pentoxifylline is taken orally after a meal. Tablets are coated with a special coating that is soluble in the intestines, so they are swallowed whole, washed down with a small amount of water. Take 200 mg (2 tablets) 3 times a day. If necessary, the dose is gradually increased to 1200 mg per day, divided into 2-3 doses. The maximum daily dose is 1200 mg. The course of treatment is 1-3 months. In patients with chronic renal failure (creatinine clearance less than 10 ml / min), the dose is halved. The duration of treatment and the dosage regimen of Pentoxifylline are determined by the attending physician individually, depending on the clinical picture of the disease and the therapeutic effect obtained.

Overdose

Symptoms: nausea, dizziness, tachycardia, marked decrease in blood pressure, redness of the skin, fever (chills), agitation, areflexia, tonic-clonic convulsions, vomiting “coffee grounds”, arrhythmias, loss of consciousness If the above-described disorders occur, the patient should immediately consult a doctor. Treatment: symptomatic. Special attention should be paid to maintaining blood pressure and respiratory function, and seizures should be relieved with diazepam. Urgent measures in case of severe anaphylactic reactions (shock): – when the first signs appear (sweating, nausea, cyanosis), immediately stop taking the drug; – in addition to other necessary measures, provide a lower position of the head and upper body and provide freedom for breathing; – urgent medical measures: introduces intravenous epinephrine (epinephrine). If necessary, the use of epinephrine can be repeated.

Special instructions

Use with caution in patients with coronary artery disease, arterial hypotension. In case of impaired renal function or severe hepatic impairment, correction of the dosage regimen of pentoxifylline is required.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 30 °C.

Shelf life

3 years

Active ingredient

Pentoxifylline

Conditions of release from pharmacies

By prescription

Dosage form

Tablets